Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for

Related Experiment Video

Updated: Aug 11, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Elisabeth H Slager1, M Willy Honders, Edith D van der Meijden

  • 1Department of Hematology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. e.h.slager@lumc.nl

Blood
|February 25, 2006
PubMed

Insights

Researchers identified a minor histocompatibility antigen from the ECGF1 gene recognized by T cells after stem cell transplantation. This discovery offers a potential target for immunotherapy in both blood cancers and solid tumors.

Area of Science:

  • Immunology
  • Oncology
  • Genetics

Background:

  • Allogeneic hematopoietic stem cell transplantation (SCT) can induce potent anti-tumor immunity.
  • Identifying specific antigens recognized by tumor-reactive T cells is crucial for developing targeted immunotherapies.

Purpose of the Study:

  • To characterize the target antigen recognized by cytotoxic T lymphocytes (CTLs) from a patient treated for multiple myeloma post-SCT.
  • To evaluate the potential of identified antigens as targets for broader cancer immunotherapy.

Main Methods:

  • Isolation of tumor-reactive CD8+ T-cell clones from a patient post-SCT.
  • cDNA expression cloning to identify the target antigen.
  • Analysis of gene expression and T-cell recognition of the identified antigen.

Main Results:

  • An HLA-B7-restricted CTL clone recognized a minor histocompatibility antigen derived from a single nucleotide polymorphism (SNP) in the ECGF1 gene (thymidine phosphorylase).
  • The SNP resulted in an amino acid substitution (Arg-to-His) in an alternatively translated peptide.
  • ECGF1 is expressed in hematopoietic cells and some other tissues, and ECGF1-specific T cells were detected in the patient with mild graft-versus-host disease.
  • The identified CTLs could lyse solid tumors expressing ECGF1.

Conclusions:

  • ECGF1 represents a novel target antigen for T-cell-based immunotherapy.
  • This antigen holds promise for treating both hematologic malignancies and solid tumors following allogeneic SCT.

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...